所属 兵庫医科大学 薬学部 医療薬学科 職種 准教授
|Glycogen synthase kinase-3beta and methamphetamine abuse liability
|Advances in Health and Disease (Lowell T. Duncan (Editor))
|Nova Science Publishers, Inc (New York)
|Junichi Kitanaka, Nobue Kitanaka, F. Scott Hall, Logan E. Kountz, Takuma Hashimoto, Kai Hirabayashi, Utau Horie, Kenta Iwasaki, Yumi Kawasaki, Minami Kimura, Takashi Sakamoto, Junya Yashiro, Kazuo Tomita, Kento Igarashi, Koh-ichi Tanaka, George R. Uhl, Tomoaki Sato, & Nobuyoshi Nishiyama
|Glycogen synthase kinase-3 (GSK-3) (EC126.96.36.199) is an essential serine/threonine kinase that has a role in a variety of physiological processes. GSK-3 is constitutively active, multifaceted, and ubiquitous in nature. In mammalian cells, GSK-has two isoforms termed GSK-3alpha and GSK-3beta. GSK-3beta is present in high concentrations in tissues in the central nervous system, having a crucial role in neuronal signaling pathways. Abnormal activity of GSK-3 is associated with neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease. In neurodegenerative disorders, GSK-3beta enzyme levels are elevated, so that the inhibition of GSK-3beta might be expected to diminish signaling dysfunctions in these conditions. Differences in GSK-3β function occur in many psychiatric and neurological conditions as well, including drug dependence, perhaps because this signaling pathway influences cell survival and synaptic plasticity.